Altered sphingolipid biosynthetic flux and lipoprotein trafficking contribute to trans fat-induced atherosclerosis - (https:/ ...

Dr. Ben Galyardt told Newsweek: "There is no drug that will treat fatty liver. There is no surgery that will fix it." ...

Kuwait: A case study published in the European Journal of Case Reports in Internal Medicine highlights the importance of ...

Controlling the dissolved oxygen in bioreactors sets the stage for developing new treatments for liver disease.

Drug-induced liver injury including cholestasis is another form of acquired liver disease, accounting for approximately 2 to 5% of hospitalizations for jaundice, 10% of cases of hepatitis in all ...

Metabolic associated fatty liver disease (MAFLD) is one of the most prevalent chronic liver diseases, with a rising incidence worldwide. In 2024, The Food and Drug Administration in the US ...

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

In acute liver diseases, such as acute liver failure, drug-induced liver injury, and viral hepatitis, bilirubin serves as a biomarker reflecting the extent of hepatocyte loss and liver damage.

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Salk scientists have tracked the flow of trans fats using mouse models to describe the molecular mechanisms that cause trans fats to promote atherosclerotic cardiovascular disease (ASCVD), explaining ...

Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patientsBoth artificial ...

The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.